Strong Revenue Growth:
Revenue is accelerating, with FY2025 up 19% and Q1 2026 up 22%, and guidance of $92–$94M implies about 20–22% further growth in 2026. Record analysis volumes and rising net dollar retention support the trajectory.
Strategic Partnerships:
High-profile collaborations with Memorial Sloan Kettering (MSK‑ACCESS and MSK‑IMPACT), AstraZeneca, MD Anderson, and large U.S. health systems expand access and credibility for new applications. These relationships are highlighted as drivers of continued double-digit growth through 2026.
Market Expansion:
The company is adding customers and scaling usage globally—reaching 537 core genomics customers and a record 108,000 analyses in Q1 2026—with particularly strong momentum in the U.S. and APAC. Reaffirmed U.S. expansion and new application launches are expected to sustain this momentum.
